Table 1 Patients’ characteristics
Degarelix (Continued group) | Conversion from degarelix to GnRH agonist (Changed group) | p value | ||||
|---|---|---|---|---|---|---|
Number of patients | 51 | 57 | ||||
Follow up duration (months) | median (range) | 19.4 | (1.0–57.9) | 38.8 | (2.2–58.6) | < 0.001 |
Degarelix treatment duration (months) | median (range) | 14 | (1–52) | 8 | (1–39) | 0.064 |
Age (years) | median (range) | 73 | (49–95) | 75 | (50–90) | 0.572 |
T stage | T1 | 3 | 5.9% | 1 | 1.8% | 0.387 |
T2 | 10 | 19.6% | 18 | 31.6% | ||
T3 | 24 | 47.1% | 26 | 45.6% | ||
T4 | 14 | 27.4% | 12 | 21.1% | ||
N | N0 | 29 | 56.9% | 31 | 54.4% | 0.796 |
N1 | 22 | 43.1% | 26 | 45.6% | ||
M | M0 | 16 | 31.4% | 23 | 40.4% | 0.486 |
M1 | 35 | 68.6% | 34 | 59.6% | ||
Gleason score | 6 | 1 | 2.0% | 2 | 3.5% | 0.389 |
7 | 5 | 9.8% | 6 | 10.5% | ||
8 | 21 | 41.2% | 24 | 42.1% | ||
9 | 15 | 29.4% | 15 | 26.3% | ||
10 | 4 | 7.8% | 5 | 8.8% | ||
unknown | 5 | 9.8% | 5 | 8.8% | ||
Initial PSA (ng/ml) | Median (range) | 145 | (0.48–8072) | 122 | (5.62–9675) | 0.669 |
PSA | PSA 0–4 | 1 | 2.0% | 0 | 0.0% | 0.415 |
PSA4–10 | 5 | 9.8% | 3 | 5.3% | ||
PSA10–20 | 2 | 3.9% | 5 | 8.8% | ||
PSA > 20 | 43 | 84.3% | 49 | 86.0% | ||
Treatment | CAB | 48 | 94.1% | 54 | 94.7% | 0.889 |
GnRH only | 3 | 5.9% | 3 | 5.3% | ||
Transition to CRPC | No | 37 | 72.5% | 38 | 66.7% | 0.508 |
Yes | 14 | 27.5% | 19 | 33.3% | ||
% PSA decrease by degarelix | median (range) | −99.4% | (6.6–100.0) | −99.8% | (47.2–100.0) | 0.068 |